S139 Efficacy of tezepelumab in patients with low and high bronchodilator reversibility in PATHWAY

• Published in: Thorax Vol. 76; no. Suppl 1; pp. A83 - A84
• Main Authors: Corren, J, Liu, MC, Bowen, K, Salapa, K, Colice, G, Llanos-Ackert, JP
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.02.2021
• Subjects: Asthma; Bronchodilators; Monoclonal antibodies
• ISSN: 0040-6376; 1468-3296
• DOI: 10.1136/thorax-2020-BTSabstracts.144

Introduction and ObjectivesIn the phase 2b PATHWAY study (NCT02054130), tezepelumab reduced annualized asthma exacerbation rates (AAER) by up to 71% versus placebo in adults with severe, uncontrolled asthma. We evaluated the effect of tezepelumab on exacerbations in patients from PATHWAY with low and high bronchodilator reversibility.MethodsAdults with severe, uncontrolled asthma were randomized to receive tezepelumab (70 mg every 4 weeks [Q4W], 210 mg Q4W or 280 mg every 2 weeks) or placebo for 52 weeks. AAER and the rate of exacerbations resulting in hospitalization or emergency room (ER) visits were estimated for patients with low (<20%) and high (≥20%) forced expiratory volume in 1 second (FEV1) reversibility at baseline.ResultsOf 550 randomized patients, 299 and 251 had low and high FEV1 reversibility, respectively. Tezepelumab 210 mg (phase 3 dose) reduced AAER over 52 weeks by 70% (95% confidence interval [CI]: 41, 85) and 72% (95% CI: 32, 88) versus placebo in patients with low and high FEV1 reversibility, respectively. For pooled tezepelumab doses, AAER was reduced by 69% (95% CI: 50, 81) and 60% (95% CI: 26, 78) in the low and high groups, respectively. Data were similar for 70 and 280 mg. Exacerbations resulting in hospitalizations or ER visits were reduced by 85% (95% CI: 21, 97) and 78% (95% CI: −32, 96) versus placebo in patients with low and high FEV1 reversibility, respectively, for tezepelumab 210 mg, and by 84% (95% CI: 51, 94) and 64% (95% CI: −18, 89) in the pooled tezepelumab group, respectively.ConclusionsTezepelumab treatment reduced AAER irrespective of baseline bronchodilator reversibility, further supporting its potential benefits in a broad population of patients with severe asthma.